ArriVent BioPharma priced its upsized Nasdaq IPO at $18 dollars per share, raising $175 million. The company’s stated goal is to find promising novel assets from China and other countries, which it aims to bring to the US market.

Beijing’s Pyrotech Therapeutics completed a $97 million Series A funding to develop novel small molecule drugs that modulate immune responses for autoimmune diseases. Meanwhile, Mirxes Holding closed a Series D funding round that raised $50 million.

Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion, HutchMed will also pay royalties on net sales.